Revance Therapeutics, Inc.

Historical 13F Holders

Symbol
RVNC
CUSIP
761330109
All holders as of
Q1 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 761330109 since 12/18/2024, largest first.

Filer % of Class Filed
Teoxane SA 13D/A 6.2% 1/30/2025
Event 1/30/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Franklin Resources, Inc. 13G/A
4.6% 10/31/2024
Event 9/30/2024
Palo Alto Investors LP 13G/A
1.5% 2/13/2025
Event 9/30/2024
Beryl Capital Management LLC 13G/A
0% 5/15/2025
Event 3/31/2025
Glazer Capital, LLC 13G/A
0% 5/15/2025
Event 3/31/2025
JPMorgan Chase & Co 13G/A 0% 3/6/2025
Event 2/28/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q1 2 86.1 k $425 k
2024 Q4 200 82.0 M $249 M
2024 Q3 229 83.4 M $432 M
2024 Q2 190 85.3 M $219 M
2024 Q1 210 88.8 M $439 M
2023 Q4 224 78.7 M $692 M
2023 Q3 220 77.9 M $893 M
2023 Q2 246 83.1 M $2.10 B
2023 Q1 248 76.7 M $2.47 B
2022 Q4 218 75.9 M $1.40 B
2022 Q3 205 67.7 M $1.82 B
2022 Q2 178 56.0 M $774 M
2022 Q1 171 54.6 M $1.06 B
2021 Q4 173 53.1 M $867 M
2021 Q3 166 54.9 M $1.53 B
2021 Q2 169 54.1 M $1.60 B
2021 Q1 156 54.8 M $1.53 B
2020 Q4 165 53.4 M $1.51 B
2020 Q3 165 49.5 M $1.25 B
2020 Q2 150 50.6 M $1.23 B
2020 Q1 138 49.5 M $732 M
2019 Q4 146 51.6 M $838 M
2019 Q3 117 42.6 M $554 M
2019 Q2 128 43.7 M $566 M
2019 Q1 120 41.7 M $657 M
2018 Q4 108 35.6 M $741 M
2018 Q3 121 34.7 M $863 M
2018 Q2 119 35.2 M $965 M
2018 Q1 127 34.4 M $1.06 B
2017 Q4 131 35.0 M $1.25 B
2017 Q3 91 27.4 M $755 M
2017 Q2 91 27.5 M $727 M
2017 Q1 83 26.4 M $549 M
2016 Q4 85 26.3 M $544 M
2016 Q3 77 28.6 M $464 M
2016 Q2 86 28.8 M $391 M
2016 Q1 90 27.3 M $477 M
2015 Q4 112 27.2 M $931 M
2015 Q3 82 21.7 M $655 M
2015 Q2 89 20.5 M $655 M
2015 Q1 72 20.6 M $426 M
2014 Q4 68 19.8 M $335 M
2014 Q3 82 15.7 M $303 M
2014 Q2 100 16.7 M $567 M
2014 Q1 67 11.9 M $376 M